Who are Silymarin capsule simulant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DA-9501.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/silymarin-capsule-simulant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Silymarin capsule simulant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Silymarin capsule simulant (Silymarin capsule simulant) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Hepatoprotective agent. Area: Hepatology / Gastroenterology.

marketed Herbal extract / Hepatoprotective agent Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Silymarin capsule simulant (Silymarin capsule simulant) — Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Silymarin is a flavonolignan mixture that protects hepatocytes through antioxidant and anti-inflammatory mechanisms, stabilizing cell membranes and promoting liver regeneration.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Silymarin capsule simulant TARGET	Silymarin capsule simulant	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Herbal extract / Hepatoprotective agent
DA-9501	DA-9501	Hospira, now a wholly owned subsidiary of Pfizer	phase 3	Herbal extract / Hepatoprotective agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Hepatoprotective agent class)

Hospira, now a wholly owned subsidiary of Pfizer · 1 drug in this class
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Silymarin capsule simulant — Competitive Intelligence Brief. https://druglandscape.com/ci/silymarin-capsule-simulant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab